BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
Gohji k., Nomi M., okamoto M., takenaka A., Hara I., okada H., Arakawa S.,<br />
Fujii A., kamidono S. (1999)<br />
Conservative therapy for stage T1b grade 3 transitional cell carcinoma of the bladder<br />
Urology, 53: 308-313<br />
Grossman H.B. (1993)<br />
Bladder Contracture following intravesical <strong>BCG</strong> Immunotherapy<br />
Urology, 41:4<br />
Grünwald L.e., SteinA., Rashcovitsky R., Shifrone G., Lurie A. (1997)<br />
A 12 versus 6-week course of Bacillus Calmette-Guérin prophylaxis for the treatment of<br />
high risk superficial bladder cancer<br />
J . Urol ., 157: 487-491<br />
Guérin c. (1957)<br />
Early history of <strong>BCG</strong> .<br />
In <strong>BCG</strong> Vaccination Against Tuberculosis . Ed S .R . Rosenthal . Boston: Little Brown<br />
pp . 48-53<br />
Haaff e.o., Dresner S.M., Ratliff t.L, catalona W.J. (1986)<br />
Two courses of intravesical Bacillus Calmette-Guérin for transitional cell carcinoma of the<br />
bladder<br />
J . Urol ., 136: 820-824<br />
Hadziev S. & kavaklieva-Dimitrova S. (1969)<br />
Applikation du <strong>BCG</strong> dans le cancer chez l’homme .<br />
J . Folia Med . Neerl ., 11, 8-14<br />
Hawkyard S.J., Jackson A.M., James k., Prescott S., Smyth J.F., chisholm G.D.<br />
(1992)<br />
The inhibitory effects of interferon gamma on the grwth of bladder cancer cells<br />
J . Urol ., 147: 1399-1403<br />
Heney N.M., Ahmed S., Flanagan M.J., et al. (1983)<br />
Superficial bladder cancer: Progression and recurrence<br />
J . Urol ., 130: 1083-1086<br />
Herr H.W., Pinsky c.M., Whitmore W.F., oetggen H.F., Melamed M.R. (1983)<br />
Effect of intravesical <strong>BCG</strong> on carcinoma in situ of the bladder<br />
Cancer, 51: 1323-1326<br />
Herr H.W., Laudome V.P., Whitmore W.F. (1987)<br />
An overview of intravesical therapy for superficial bladder tumors<br />
J . Urol ., 138: 1363-1368<br />
Herr H.W., Whitmore W.F. (1987)<br />
Urethral carcinoma in situ after successful intravesical therapy for superficial bladder<br />
tumors: Incidence, posible pathogenesis and management<br />
J . Urol ., 138, 292-294<br />
Herr H.W. (1992a)<br />
Intravesical <strong>BCG</strong>: current results, natural history, and implications for urothelial cancer prevention<br />
J . Cell . Biochem ., Suppl ., 161: 112-119<br />
Hillyard R.W., Ladaga L., Schellhammer P.F. (1988)<br />
Superficial Transitional Cell Carcinoma Of The Bladder Associated With Mucosal<br />
Involvement Of The Prostatic Urethra: Results Of Treatment With Intravesical Bacillus<br />
Calmette-Guérin<br />
J . Urol ., 139: 290-293<br />
Holmgren I. (1935)<br />
La tuberculine et le <strong>BCG</strong> chez les cancereux<br />
Schweiz . Med . Wochenschr ., 65: 1203-1206<br />
Hrouda D., Muir G.H., Dalgleisch A.G. (1997)<br />
The role of immunotherapy for urological tumors<br />
Brit . J . Urol ., 79: 307-316<br />
65
Change language